相似文献
1
Sulfonylurea treatment in type 2 diabetes.2型糖尿病的磺脲类药物治疗
Can Fam Physician. 2018 Apr;64(4):295.
2
[Not Available].[无可用内容]。
Ther Umsch. 2017;74(8):423-431. doi: 10.1024/0040-5930/a000936.
3
Pioglitazone/glimepiride (Duetact) for diabetes.吡格列酮/格列美脲（Duetact）用于治疗糖尿病。
Med Lett Drugs Ther. 2007 Jan 29;49(1253):9-11.
4
Sulphonylureas in the treatment of non-insulin-dependent diabetes.磺脲类药物治疗非胰岛素依赖型糖尿病
Q J Med. 1989 Nov;73(271):987-95.
5
Glimepiride for NIDDM.格列美脲用于非胰岛素依赖型糖尿病。
Med Lett Drugs Ther. 1996 May 24;38(975):47-8.
6
The second-generation sulfonylureas: change or progress?第二代磺脲类药物：是变革还是进步？
Ann Intern Med. 1985 Jan;102(1):125-6. doi: 10.7326/0003-4819-102-1-125.
7
Rosiglitazone/glimepiride (Avandaryl) for diabetes.罗格列酮/格列美脲（文迪雅）用于治疗糖尿病。
Med Lett Drugs Ther. 2006 Mar 13;48(1230):22-4.
8
Pioglitazone + glimepiride: a combination product to avoid.吡格列酮+格列美脲：一种应避免使用的复方制剂。
Prescrire Int. 2007 Aug;16(90):145.
9
[Safety is the issue again].
MMW Fortschr Med. 2013 Oct 10;155(17):26. doi: 10.1007/s15006-013-2217-x.
10
Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.磺脲类药物治疗非胰岛素依赖型糖尿病和冠状动脉疾病的潜在风险。
Diabetologia. 1998 Jun;41(6):743-4. doi: 10.1007/s001250050981.
引用本文的文献
1
Simultaneous Determination of Glibenclamide and Silymarin Released from Chitosan Microparticles by HPLC-ESI-MS Technique: Method Development and Validation.采用高效液相色谱-电喷雾电离质谱联用技术同时测定壳聚糖微粒中释放的格列本脲和水飞蓟素：方法建立与验证
Pharmaceutics. 2022 Oct 11;14(10):2164. doi: 10.3390/pharmaceutics14102164.
本文引用的文献
1
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.吡格列酮与磺脲类药物联合治疗二甲双胍控制不佳的 2 型糖尿病患者心血管事件发生率的影响（TOSCA.IT）：一项随机、多中心试验。
Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13.
2
The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.甘精胰岛素与格列美脲对二甲双胍单药治疗血糖控制不佳的2型糖尿病患者胰岛β细胞功能的影响：开放标签、随机对照研究
Acta Diabetol. 2014 Apr;51(2):277-85. doi: 10.1007/s00592-013-0553-z. Epub 2014 Jan 21.
3
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.磺酰脲类药物与心血管疾病风险：系统评价和荟萃分析。
Diabet Med. 2013 Oct;30(10):1160-71. doi: 10.1111/dme.12232.
4
Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.二甲双胍与格列吡嗪对 2 型糖尿病合并冠心病患者心血管结局的影响。
Diabetes Care. 2013 May;36(5):1304-11. doi: 10.2337/dc12-0719. Epub 2012 Dec 10.
5
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.二甲双胍控制不佳的 2 型糖尿病患者中利拉利汀与格列美脲的 2 年疗效和安全性比较：一项随机、双盲、非劣效性试验。
Lancet. 2012 Aug 4;380(9840):475-83. doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.
6
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.罗格列酮、二甲双胍或格列本脲单药治疗的血糖耐久性。
N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4.
7
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.对于二甲双胍和噻唑烷二酮治疗控制不佳的2型糖尿病患者，使用格列美脲进行三联疗法：一项为期30周的随机、双盲、安慰剂对照、平行组研究的结果。
Clin Ther. 2005 Oct;27(10):1535-47. doi: 10.1016/j.clinthera.2005.10.017.
8
Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study.
Diabetes Care. 2003 Aug;26(8):2353-8. doi: 10.2337/diacare.26.8.2353.
9
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.磺脲类或胰岛素强化血糖控制与传统治疗及2型糖尿病患者并发症风险的比较（英国前瞻性糖尿病研究[UKPDS 33]）。英国前瞻性糖尿病研究（UKPDS）小组
Lancet. 1998 Sep 12;352(9131):837-53.
10
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.α-葡萄糖苷酶抑制剂作为老年2型糖尿病患者单一疗法的优势。
J Clin Endocrinol Metab. 1998 May;83(5):1515-22. doi: 10.1210/jcem.83.5.4824.
Zotero 插件